Articles from Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ModivCare, Inc. (“ModivCare” or the “Company”) (NASDAQMODV) securities between November 3, 2022 and September 15, 2024, inclusive (the “Class Period”). ModivCare investors have until March 31, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP reminds investors of the upcoming March 31, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired TELUS International (Cda) Inc. (“Telus International” or the “Company”) (NYSETIXT) securities between February 16, 2023 and August 1, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP reminds investors of the upcoming March 24, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Crocs, Inc. (“Crocs” or the “Company”) (NASDAQCROX) common stock between November 3, 2022 and October, 28 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Integral Ad Science Holding Corp. (“IAS” or the “Company”) (NASDAQIAS) common stock between March 2, 2023, and February 27, 2024, inclusive (the “Class Period”). IAS investors have until March 31, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ModivCare, Inc. (“ModivCare” or the “Company”) (NASDAQMODV) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Malibu Boats, Inc. (Nasdaq: MBUU) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Sarria v. TELIS International (Cda) Inc., et al., Case No. 1:25-cv-00889, on behalf of persons and entities that purchased or otherwise acquired TELUS International (Cda) Inc. (“Telus International” or the “Company”) (NYSETIXT) securities between February 16, 2023 and August 1, 2024, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Crocs, Inc. (“Crocs” or the “Company”) (NASDAQCROX) common stock between November 3, 2022 and October, 28 2024, inclusive (the “Class Period”). Crocs investors have until March 24, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Enovix Corporation (Nasdaq: ENVX) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MaxCyte, Inc. (NASDAQMXCT) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Construction Partners, Inc. (“Construction Partners” or the “Company”) (NASDAQROAD) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Triumph Financial, Inc. (“Triumph” or the “Company”) (NASDAQTFIN) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Georgia, captioned Froess v. Cardlytics, Inc., et al., Case No. 1:25-cv-279, on behalf of persons and entities that purchased or otherwise acquired Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) securities between March 14, 2024 and August 7, 2024, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP reminds investors of the upcoming March 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Block, Inc. (“Block” or the “Company”) (NYSE: SQ; XYZ) Class A common stock between February 26, 2020 and April 30, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Crocs, Inc. (“Crocs” or the “Company”) (NASDAQCROX) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP reminds investors of the upcoming March 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQFTAI) securities between July 23, 2024 and January 15, 2025, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Block, Inc. (“Block” or the “Company”) (NYSE: SQ; XYZ) Class A common stock between February 26, 2020 and April 30, 2024, inclusive (the “Class Period”). Block investors have until March 18, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Shannahan v. FTAI Aviation Ltd., et al., Case No. 25-cv-541, on behalf of persons and entities that purchased or otherwise acquired FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQFTAI) securities between July 23, 2024 and January 15, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TELUS International (Cda) Inc. (“TELUS” or the “Company”) (NYSETIXT) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Ocean Power Technologies, Inc. (NYSEOPTT) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQGLSI) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of PVH Corp. (“PVH” or the “Company”) (NYSEPVH) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQCDLX) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQFTAI) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQBIOA) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s September 2024 initial public offering (the “IPO” or the “Offering”).

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of GameStop Corp. (NYSEGME) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Climb Global Solutions, Inc. (NASDAQCLMB) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Huntington Ingalls Industries, Inc. (“Huntington Ingalls” or the “Company”) (NYSEHII) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Asure Software, Inc. (NASDAQASUR) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Broadwind, Inc. (NASDAQBWEN) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Progyny, Inc. (“Progyny” or the “Company”) (NASDAQPGNY) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP reminds investors of the upcoming February 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nextracker Inc. (“Nextracker” or the “Company”) (NASDAQNXT) common stock between February 1, 2024 and August 1, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). Regeneron investors have until March 10, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQBIOA) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s September 2024 initial public offering (the “IPO” or the “Offering”). BioAge investors have until March 10, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of (“BioAge” or the “Company”) (NASDAQBIOA) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP reminds investors of the upcoming February 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Joint Stock Company Kaspi.kz (“Kaspi” or the “Company”) (NASDAQKSPI) securities between January 19, 2024 and September 19, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capri Holdings Limited (“Capri” or the “Company”) (NYSECPRI) securities or sold puts between August 10, 2023 and October 24, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Nextracker Inc. (“Nextracker” or the “Company”) (NASDAQNXT) common stock between February 1, 2024 and August 1, 2024, inclusive (the “Class Period”). Nextracker investors have until February 25, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Radtke v. Regeneron Pharmaceuticals, Inc., et al., Case No. 25-cv-145, on behalf of persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). Revance investors have until March 4, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSETFX) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Gatos Silver, Inc. (NYSE/TSX: GATO) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP reminds investors of the upcoming February 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQAPLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Joint Stock Company Kaspi.kz (“Kaspi” or the “Company”) (NASDAQKSPI) securities between January 19, 2024 and September 19, 2024, inclusive (the “Class Period”). Kaspi investors have until February 18, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Capri Holdings Limited (“Capri” or the “Company”) (NYSECPRI) securities or sold puts between August 10, 2023 and October 24, 2024, inclusive (the “Class Period”). Capri investors have until February 21, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). AstraZeneca investors have until February 21, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQSGMO) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQAPLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”). Applied Therapeutics investors have until February 18, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nextracker Inc. (“Nextracker” or the “Company”) (NASDAQNXT) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capri Holdings Limited (“Capri” or the “Company”) (NYSECPRI) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 24, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Transocean Ltd. (“Transocean” or the “Company”) (NYSERIG) securities between October 31, 2023 and September 2, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Gábor v. Transocean Ltd., et al., Case No. 1:24-cv-09964, on behalf of persons and entities that purchased or otherwise acquired Transocean Ltd. (“Transocean” or the “Company”) (NYSE: RIG,) securities between October 31, 2023 and September 2, 2024, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Sun Communities, Inc. (“Sun Communities” or the “Company”) (NYSESUI) securities between February 28, 2019 and September 24, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MGP Ingredients, Inc. (“MGPI” or the “Company”) (NASDAQMGPI) common stock between May 4, 2023 through October 30, 2024,, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Sun Communities, Inc. (“Sun Communities” or the “Company”) (NYSESUI) securities between February 28, 2019 and September 24, 2024, inclusive (the “Class Period”). Sun Communities investors have until February 10, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MGP Ingredients, Inc. (“MGPI” or the “Company”) (NASDAQMGPI) common stock between May 4, 2023 through October 30, 2024, inclusive (the “Class Period”). MGPI investors have until February 14, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQKYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 2024 initial public offering (the “IPO” or the “Offering”).

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 3, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Five9, Inc. (“Five9” or the “Company”) (NASDAQFIVN) securities between June 4, 2024 and August 8, 2024,, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 4, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DMC Global Inc. (“DMC” or the “Company”) (NASDAQBOOM) securities between May 3, 2024 and November 4, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQKYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 2024 initial public offering (the “IPO” or the “Offering”). Kyverna investors have until February 7, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Marqeta, Inc. (“Marqeta” or the “Company”) (NASDAQMQ) securities between May 7, 2024 and November 4, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Five9, Inc. (“Five9” or the “Company”) (NASDAQFIVN) securities between June 4, 2024 and August 8, 2024, inclusive (the “Class Period”). Five9 investors have until February 3, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 31, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Customers Bancorp, Inc. (“Customers Bancorp” or the “Company”) (NYSECUBI) securities between March 1, 2024 and August 8, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 3, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aehr Test Systems, Inc. (“Aehr” or the “Company”) (NASDAQAEHR) securities between January 9, 2024 and March 24, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQAPLT) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Five9, Inc. (“Five9” or the “Company”) (NASDAQFIVN) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQKYTX) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Marqeta, Inc. (“Marqeta” or the “Company”) (NASDAQMQ) securities between May 7, 2024 and November 4, 2024, inclusive (the “Class Period”). Marqeta investors have until February 7, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired DMC Global Inc. (“DMC” or the “Company”) (NASDAQBOOM) securities between May 3, 2024 and November 4, 2024, inclusive (the “Class Period”). DMC investors have until February 4, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Customers Bancorp, Inc. (“Customers Bancorp” or the “Company”) (NYSECUBI) securities between March 1, 2024 and August 8, 2024, inclusive (the “Class Period”). Customers Bancorp investors have until January 31, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Aehr Test Systems, Inc. (“Aehr” or the “Company”) (NASDAQAEHR) securities between January 9, 2024 and March 24, 2024, inclusive (the “Class Period”). Aehr investors have until February 3, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Veradigm Inc. (OTCMKTS: MDRX) concerning the Company and its directors’ and officers’ possible violations of state laws.